Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
28 09 2021
Historique:
accepted: 20 07 2021
entrez: 23 9 2021
pubmed: 24 9 2021
medline: 5 10 2021
Statut: ppublish

Résumé

Human metapneumovirus (HMPV) is a major cause of respiratory disease worldwide, particularly among children and the elderly. Although there is no licensed HMPV vaccine, promising candidates have been identified for related pneumoviruses based on the structure-based stabilization of the fusion (F) glycoprotein trimer, with prefusion-stabilized F glycoprotein trimers eliciting significantly higher neutralizing responses than their postfusion F counterparts. However, immunization with HMPV F trimers in either prefusion or postfusion conformations has been reported to elicit equivalent neutralization responses. Here we investigate the impact of stabilizing disulfides, especially interprotomer disulfides (IP-DSs) linking protomers of the F trimer, on the elicitation of HMPV-neutralizing responses. We designed F trimer disulfides, screened for their expression, and used electron microscopy (EM) to confirm their formation, including that of an unexpected postfusion variant. In mice, IP-DS-stabilized prefusion and postfusion HMPV F elicited significantly higher neutralizing responses than non-IP-DS-stabilized HMPV Fs. In macaques, the impact of IP-DS stabilization was more measured, although IP-DS-stabilized variants of either prefusion or postfusion HMPV F induced neutralizing responses many times the average titers observed in a healthy human cohort. Serological and absorption-based analyses of macaque responses revealed elicited HMPV-neutralizing responses to be absorbed differently by IP-DS-containing and by non-IP-DS-containing postfusion Fs, suggesting IP-DS stabilization to alter not only the immunogenicity of select epitopes but their antigenicity as well. We speculate the observed increase in immunogenicity by IP-DS trimers to be related to reduced interprotomer flexibility within the HMPV F trimer.

Identifiants

pubmed: 34551978
pii: 2106196118
doi: 10.1073/pnas.2106196118
pmc: PMC8488613
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Disulfides 0
Epitopes 0
Glycoproteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

N Engl J Med. 2015 Jul 30;373(5):415-27
pubmed: 26172429
J Infect Dis. 2002 Nov 1;186(9):1330-4
pubmed: 12402203
N Engl J Med. 2015 Feb 26;372(9):835-45
pubmed: 25714161
J Infect Dis. 2012 Jul 1;206(1):56-62
pubmed: 22529314
J Virol. 2015 Sep;89(18):9499-510
pubmed: 26157122
NPJ Vaccines. 2017 Mar 8;2:7
pubmed: 29021918
Int J Infect Dis. 2014 Aug;25:45-52
pubmed: 24841931
J Infect Dis. 2004 Apr 15;189(8):1388-96
pubmed: 15073675
J Infect Dis. 2002 Jun 1;185(11):1660-3
pubmed: 12023774
PLoS Pathog. 2016 Sep 09;12(9):e1005859
pubmed: 27611367
Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):12265-12270
pubmed: 30420505
N Engl J Med. 2004 Jan 29;350(5):443-50
pubmed: 14749452
Science. 2013 May 31;340(6136):1113-7
pubmed: 23618766
Nat Med. 2001 Jun;7(6):719-24
pubmed: 11385510
Nat Commun. 2015 Sep 03;6:8143
pubmed: 26333350
Emerg Infect Dis. 2003 Jun;9(6):628-33
pubmed: 12781000
Sci Transl Med. 2015 Oct 14;7(309):309ra162
pubmed: 26468324
Vaccine. 2020 Feb 24;38(9):2122-2127
pubmed: 32007293
Virus Res. 2003 Feb;91(2):163-9
pubmed: 12573494
Science. 2013 Nov 1;342(6158):592-8
pubmed: 24179220
J Infect Dis. 2003 Mar 1;187(5):785-90
pubmed: 12599052
J Pediatric Infect Dis Soc. 2016 Sep;5(3):303-11
pubmed: 26407261
Nat Commun. 2017 Nov 16;8(1):1528
pubmed: 29142300
Viral Immunol. 2018 Mar;31(2):133-141
pubmed: 29323621
Pathog Immun. 2019 Dec 11;4(2):294-323
pubmed: 31893251
PLoS One. 2015 Jun 22;10(6):e0128779
pubmed: 26098893
Virology. 2002 Mar 30;295(1):119-32
pubmed: 12033771
Science. 2019 Aug 2;365(6452):505-509
pubmed: 31371616
J Allergy Clin Immunol. 2005 Jun;115(6):1311-2
pubmed: 15940152
Nature. 2013 Sep 19;501(7467):439-43
pubmed: 23955151
J Infect Dis. 2003 Nov 15;188(10):1571-7
pubmed: 14624384
Nat Struct Mol Biol. 2016 Sep;23(9):811-820
pubmed: 27478931

Auteurs

Guillaume B E Stewart-Jones (GBE)

Vaccine Research Center, NIH, Bethesda, MD 20892.

Jason Gorman (J)

Vaccine Research Center, NIH, Bethesda, MD 20892.
National Resource for Automated Molecular Microscopy, Simons Electron Microscopy Center, New York Structural Biology Center, New York, NY 10027.

Li Ou (L)

Vaccine Research Center, NIH, Bethesda, MD 20892.

Baoshan Zhang (B)

Vaccine Research Center, NIH, Bethesda, MD 20892.

M Gordon Joyce (MG)

Vaccine Research Center, NIH, Bethesda, MD 20892.
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Silver Spring, MD 20910.

Lijuan Yang (L)

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.

Cheng Cheng (C)

Vaccine Research Center, NIH, Bethesda, MD 20892.

Gwo-Yu Chuang (GY)

Vaccine Research Center, NIH, Bethesda, MD 20892.

Kathryn E Foulds (KE)

Vaccine Research Center, NIH, Bethesda, MD 20892.

Wing-Pui Kong (WP)

Vaccine Research Center, NIH, Bethesda, MD 20892.

Adam S Olia (AS)

Vaccine Research Center, NIH, Bethesda, MD 20892.

Mallika Sastry (M)

Vaccine Research Center, NIH, Bethesda, MD 20892.

Chen-Hsiang Shen (CH)

Vaccine Research Center, NIH, Bethesda, MD 20892.

John-Paul Todd (JP)

Vaccine Research Center, NIH, Bethesda, MD 20892.

Yaroslav Tsybovsky (Y)

Electron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.

Raffaello Verardi (R)

Vaccine Research Center, NIH, Bethesda, MD 20892.

Yongping Yang (Y)

Vaccine Research Center, NIH, Bethesda, MD 20892.

Peter L Collins (PL)

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.

Davide Corti (D)

Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Humabs BioMed SA, 6500 Bellinzona, Switzerland.

Antonio Lanzavecchia (A)

Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.

Diana G Scorpio (DG)

Vaccine Research Center, NIH, Bethesda, MD 20892.

John R Mascola (JR)

Vaccine Research Center, NIH, Bethesda, MD 20892; pdkwong@nih.gov ubuchholz@niaid.nih.gov jmascola@nih.gov.

Ursula J Buchholz (UJ)

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892; pdkwong@nih.gov ubuchholz@niaid.nih.gov jmascola@nih.gov.

Peter D Kwong (PD)

Vaccine Research Center, NIH, Bethesda, MD 20892; pdkwong@nih.gov ubuchholz@niaid.nih.gov jmascola@nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH